英夫利西单抗治疗中重度活动性克罗恩病的疗效及安全性  

Efficacy and Safety of Infliximab in Treating Patients with Severe Active Crohn's Disease

作　　者：兰雨桐 刘威宇 邢俊伟 来爽 杨慧珊[1] 李虹[1] 邓秋萍 刘维新[1] LAN Yutong;LIU Weiyu;XING Junwei;LAI Shuang;YANG Huishan;LI Hong;DENG Qiuping;LIU Weixin(Department of Digestive Diseases,The First Hospital,China Medical University,Shenyang 110001,China;The Second Department of Digestive Diseases,The People’s Hospital of Liaoning Province,Shenyang 110013,China;Department of Digestive Diseases,Yingkou Central Hospital,Yingkou 115003,China)

机构地区：[1]中国医科大学附属第一医院消化内科,沈阳110001 [2]辽宁省人民医院消化二科,沈阳110013 [3]营口市中心医院消化内科,辽宁营口115003

出　　处：《中国医科大学学报》2018年第4期333-337,共5页Journal of China Medical University

基　　金：辽宁省科学技术计划(2013225303)

摘　　要：目的 观察英夫利西单抗(IFX)治疗克罗恩病(CD)的疗效与安全性。方法 回顾性分析42例传统药物疗效差或再次复发的CD患者应用IFX治疗的疗效,评估疾病活动度、血生化指标、并发症、结肠镜结果及药物的安全性。结果 42例患者经IFX治疗14周,39例达到临床有效,34例达到临床缓解,CD活动指数(CDAI)评分、C反应蛋白(CRP)、血沉、血小板计数均明显下降(P<0.05)。21例患者经IFX治疗38周,CDAI评分、CRP、血沉、血小板计数明显下降(P<0.05),而血红蛋白、白蛋白明显升高(P<0.05)。7例肛瘘均有不同程度缓解。不良反应仅5次。结论 IFX对经传统药物治疗效果不佳或再次复发的CD患者效果良好,近期不良反应率较低,总体安全。Objective To observe the efficacy and safety of infliximab(IFX)for the treatment of patients with Crohn’s disease(CD).Methods We retrospectively analyzed the efficacy of IFX therapy in 42 patients with active CD who had shown no obvious improvement or had shown relapse after treatment with traditional medicine.The change in disease activity,blood biochemical indices,complications,and colonoscopic examination results were compared and analyzed.Results Among the 42 patients who received IFX therapy,39 achieved clinical efficacy and 34 achieved clinical remission.In these 42 patients,the CD activity index score,C-reactive protein,erythrocyte sedimentation rate,and platelet count were significantly decreased(P<0.05).In 21 patients receiving IFX treatment for 38 weeks,the CD activity index score,C-reactive protein,erythrocyte sedimentation rate,and platelet count were significantly decreased,and the hemoglobin and albumin levels were significantly increased(P<0.05).Seven patients with an anal fistula showed varying degrees of symptom relief.Adverse reactions occurred in only 5 patients during the treatment.Conclusion IFX is effective in patients with a poor response to or relapse with the use of traditional medicine.The incidence of adverse reactions is low and overall,IFX is a safe drug.

关 键 词：英夫利西单抗 克罗恩病 疗效 安全性 

分 类 号：R574[医药卫生—消化系统]